Tobacco consumption remains the most important avoidable cancer risk and smoking causes 90% of all lung cancers. The vast majority of cigarette smokers who try to quit ultimately fail because of high relapse rates. Our first Smoking Cessation could not be more timely. With the first prescription medication approved in almost a decade for smoking cessation and recent smoking bans in countries, especially in England. The anti-smoking pipeline looks promising with a total of 17 drugs with new targets. The launch of new therapies, such as the vaccines and MAO inhibitors, expected to hit the market in late 2009 and early 2010 will have a major impact on the overall drive of the market in terms of revenue. As health authorities seek to reduce overall healthcare expenditure on smoking related disorders. The Smoking Cessation conference will provide the ideal strategic forum for researchers, clinicians, pharma, and biotech to examine current and future smoking cessation therapies, and assess the factors influencing the market, from new product developments to distribution and pricing issues.
Reasons to register today :
Explore the prospects for long term efficacy of new classes of no nicotinic drugs in development
Identify novel therapeutic targets to improve smoking cessation
Examine potential market opportunities for new anti-smoking products
Discuss the regulatory considerations for therapeutic vaccination
Increase the cost-effectiveness and benefi ts of smoking cessation aids
Hear from expert figures of all areas of the industry, collaborating and sharing knowledge at one venue
I look forward to meeting you at the conference
Best regards
Andrea Charles
Conference Producer
Pharmaceutical Division
------------------------------------------------------------
Who will be there?
Companies :
Pharmaceutical and biotech companies
Academics
Regulatory organisations
Trade organisations
Healthcare professionals
VPs, Directors, Heads and Managers of :
Research and Development
Business Development
Commerical development
Clinical Trials
Clinical Pharmacology
Drug Delivery
Smoking Cessation/ Anti-smoking products
Outcomes Research
Pricing
Reimbursement and Access
Marketing
Product management
------------------------------------------------------------
Day 1 - SMOKING CESSATION 2008 - WEDNESDAY 30TH JANUARY 2008
09:00 Registration & refreshments
09:30 Chairs’ opening remarks
09:40 Examining the current market potential for new anti-smoking products
• Identifying market drivers and restraints
• Nicotine Replacement Therapy (NRT): The current heavyweight!
• Can any product compete with a OTC nicotine gum?
• The antidepressant approach: Bupropion (Zyban)
• Pfizer’s Chantix / Champix
• Sanofi ’s Dianicline
• Future contenders:
- nicotine metabolism inhibitors
- nicotine vaccines
10.20 Developing therapeutic vaccinations for smoking cessation
• Therapeutic benefi ts: Cigarette smoking has been identified as the most important source of preventable morbidity and premature mortality worldwide
• Examining current therapies and the requirement for a novel strategy of treatment
• Overview of the therapeutic vaccines against smoking
• Pre-clinical and clinical evidence to support the induction of antibodies to nicotine and the regulatory hormones involved
• Regulatory compliance
Martin Bachmann
Executive Vice President & Chief Executive Officer
Cytos Biotechnology*
11:00 Morning refreshments
11.20 NicVax: Next steps
• NicVAX® (Nicotine Conjugate Vaccine) is an investigational
• Vaccine designed as an aid to smoking cessation, as well as an aid to prevent relapses of a treated smoker
• Overview of key findings to date
• Complete Phase 2b trial and 12-month data analysis
• Complete design of optimal protocol
Dr Matthew W Kalnik
Vice President, Business Development and Project Management
Nabi Biopharmaceuticals
12:10 Varenicline:
• Varenicline:
• Varenicline is an 4 2 nicotinic acetylcholine receptor partial agonist.
• Reducing the satisfaction of continued smoking
• Producing partial activation at nicotinic receptors to ease craving and withdrawal symptoms
• Simultaneously blocking the effects of nicotine from cigarettes smoked
• Effi cacy and safety of varenicline for smoking cessation
Alex Bobak
GP
Wandsworth PCT London*
12:50 Networking lunch
14.10 Rimonabant for smoking cessation
• What is rimonabant ?
• What is the evidence for its use in smoking cessation ?
• Could it prevent weight gain after smoking ?
• How safe is it?
Kate Cahill
Review group co-ordinator
Cochrane Tobacco Addiction Group
14.50 The impact of smoking cessation on the course of respiratory disease
• Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy
• The need for effective smoking cessation strategies
• Smoking and COPD: patients with COPD, an annual quit rate of around 15%
• Development of smoking cessation interventions for people with COPD
• Prospects for long term effi cacy of new classes of non-nicotinic drugs in development
Professor Philip Tønnesen
Chair, dept Pulmonary Medicine
Gentofte University Hospital
15:30 Afternoon refreshments
15:50 Smoking cessation in primary care
Dr Anders Østrem
General Practitioner
President, International Primary Care
Respiratory Group
16:30 Maintaining a critical competitive advantage
• Marketing approach of the tobacco industry
• What they do well to attract customers
• Utilising what they do well to beat them at their own game
Keith Burnett
Delivery Manager (North)
Department of Health Tobacco Control
National Support Team
17.10 Chair’s closing remarks
17.20 Networking Drinks
Take your discussions further and build new relationships in a relaxed and informal setting.
For more information kindly visit: http://www.bharatbook.com/
